← Krystal Biotech, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($1.1m) ($7.9m) ($10.9m) ($19.1m) ($32.2m) ($69.6m) ($140.0m) $10.9m $89.2m $204.8m
Net Income (Loss) Available to Common Stockholders, Basic ($1.1m) ($7.9m) ($10.9m) ($19.1m) ($32.2m) ($69.6m) ($140.0m) $10.9m $89.2m $204.8m
Depreciation, Depletion and Amortization $2k $23k $141k $748k $1.9m $2.8m $2.6m $5.0m $6.0m $5.7m
Depreciation $2k $23k $141k $748k $1.5m $1.8m $2.6m $5.0m $6.0m $5.7m
Amortization — — — — — — $1.4m ($1.3m) — —
Deferred Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $0 — — — ($27.3m)
Share-based Payment Arrangement, Noncash Expense $33k $246k $792k $1.2m $3.3m $15.3m $33.2m $39.9m $49.1m $54.5m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — $0 $649k $749k — —
Share-based Payment Arrangement, Expense $33k $246k $792k $1.2m $3.3m $13.7m — — — $54.5m
Gain (Loss) on Disposition of Intangible Assets — — — — — — $0 $100.0m $0 $0
Gain (Loss) on Disposition of Assets for Financial Service Operations — — — ($67k) ($33k) $0 ($72k) ($27k) — —
Income Tax Expense (Benefit) — $0 $0 $0 $0 $0 $0 $2.0m $6.2m ($15.4m)
Operating Lease, Expense — — — — $756k $1.3m — — — —
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable — — — — — — $0 $42.0m $62.7m $22.1m
Increase (Decrease) in Inventories — — — — — — $0 $4.5m $11.9m $6.3m
Increase (Decrease) in Accounts Payable $42k $133k $112k ($199k) $783k $712k ($1.3m) ($101k) $1.0m $826k
Proceeds from Stock Options Exercised — — — — — — $7.0m $43.8m $32.4m $22.7m
Foreign Currency Transaction Gain (Loss), before Tax — — — — — — — — — ($1.2m)
Gain (Loss) Related to Litigation Settlement — — — — — $560k — — — $0
General and Administrative Expense $402k $1.6m $4.2m $6.5m $15.1m $40.4m $77.7m $98.4m — —
Nonoperating Income (Expense) ($7k) ($3.1m) — — — — — — — —
Operating Expenses $1.1m $4.8m $11.9m $22.1m $33.0m $68.3m $145.2m $160.4m $224.8m $227.8m
Realized Investment Gains (Losses) — — — — — — $570k $5.1m $6.1m $6.0m
Net Cash Provided by (Used in) Operating Activities ($1.3m) ($3.9m) ($9.4m) ($18.7m) ($26.1m) ($47.9m) ($100.6m) ($88.8m) $123.4m $200.9m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $15k $210k $2.2m $6.4m $14.8m $68.3m $53.0m $11.8m $4.2m $12.0m
Net Cash Provided by (Used in) Investing Activities — — ($10.3m) ($5.0m) ($11.2m) ($226.8m) ($114.1m) $82.6m ($163.4m) ($58.4m)
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $100k $42.5m $73.8m $107.5m $118.0m $355.6m $36.0m $203.5m $0 $0
Net Cash Provided by (Used in) Financing Activities $3.2m $51.8m $73.8m $107.5m $118.0m $347.7m $35.3m $202.8m $27.0m $8.7m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — $0 $0 ($41k) ($156k) ($458k) $286k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — — — $80.8m $73.0m ($179.3m) $196.4m ($13.5m) $151.4m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — $268.3m $341.2m $161.9m $358.3m $344.9m $496.3m
Cash, Cash Equivalents, and Short-term Investments — — — $193.7m $271.3m $438.1m — $532.2m $597.5m $827.8m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net — — — — $0 $0 $0 $0 $5.7m $14.8m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.